Research & Development
EMA to decide on Pfizer's COVID-19 booster shot in early October
23 September 2021 -

The European Medicines Agency (EMA), the EU's drug regulator, is expected to decide in early October on the possible use of a booster dose of the Pfizer (NYSE:PFE)/BioNTech (Nasdaq:BNTX) COVID-19 vaccine, Reuters news agency reported on Thursday, citing a source with direct knowledge of the matter.

According to the source, this will be the EMA's first decision on COVID-19 vaccine boosters.

The regulator said on 6 September that it had begun its evaluation of data submitted by Pfizer and BioNTech for a booster dose to be given six months after the second dose in people 16 years of age and older.

Login
Username:

Password:


Related Headlines

Dr. Reddy's Laboratories unveils Carmustine for Injection, USP in the US Market

FDA Approves Merck's Keytruda Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients with Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)

Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer

FDA Approves Merck's Keytruda Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients with Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin's Lymphoma

Sobi and Apellis report positive opinion by EMA committee

Detect to accelerate manufacturing of PCR-Quality Rapid At-Home Covid-19 Test under NIH RADxSM initiative and President Biden's Covid-19 Action Plan

Moderna expects the FDA advisory committee to support emergency use of booster COVID-19 Vaccine dose in the US

Cantargia receives positive EMA opinion for orphan designation of nadunolimab in pancreatic cancer

Eli Lilly's Verzenio(R) (abemaciclib) and endocrine therapy combination gains US FDA breast cancer treatment approval

Novartis's Beovu(R) receives FDA and EMA filing acceptances for patients with diabetic macular edema

Eli Lilly wins FDA approval of Verzenio for treatment of HR+ HER2- high risk early breast cancer

Kiromic BioPharma Forges Strategic Collaboration with Gemelli Teaching Hospital to Accelerate the Analysis of Allogeneic CAR-T Clinical Trial Candidate Alexis ISO-1 in Solid Cancers

Revance confident of FDA approval of DaxibotulinumtoxinA for Injection

US FDA scientists state Moderna does not meet all criteria for COVID-19 boosters